MAYO CLINIC LABORATORIES

1-800-533-1710

KI67P

Ki-67(MIB-1), Pulmonary, Quantitative Immunohistochemistry, Automated

Patient ID	Patient Name		Birth Date	Gender	Age
SA00143552	TESTING, KI67P ABNORMAL		1981-12-26	F	39
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00143552	SA00143552	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		22 Mar 2021 00:00			

Ki67 Pulmonary IHC Automated

Case Number CR-21-349

Interpretation

MCR

Right Upper Lobe, original accession: SA-21–345, block: SA-21–345-A1

SPECIAL PROCEDURE REPORT

Biomarker(s) for:
Carcinoid/Atypical Carcinoid tumor

Result(s):

Ki-67 labeling index:

The block contains marginally sufficient neoplastic representation. Thus, retesting of subsequent excisional specimens is recommended if clinically indicated.

Labeling Index: 50 %
(>20%)

METHOD AND SCORING

Ki-67 Neuroendocrine Automated Method: Immunohistochemical staining of the Ki-67 antigen in formalin-fixed paraffin-embedded tissue sections has been validated by our laboratory, using the Dako mouse monoclonal MIB-1 clone and a proprietary detection system. All controls show appropriate reactivity. Ki-67 quantification using the Aperio system in neuroendocrine tumors (NET) has been validated by our laboratory. Ki-67 stained slides are scanned using the Aperio ScanScope instrument, which captures digital images of the patient slide. A technologist views the digitized image and selects the most intensely stained area ("hot-spot") within the tumor. Then, using a rectangle tool available in ImageScope (Aperio Technologies Inc), lays up to ten annotations in this "hot-spot" which are analyzed using an image analysis algorithm that renders the percentage of positive staining tumor nuclei. The slides, images and test results are then reviewed by a pathologist who provides a final interpretation. This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

1. Boland J, et al. Ki-67 Labeling Index in Pulmonary Carcinoid Tumors: Comparison Between Small Biopsy and Resection Using Tumor Tracing and Hot Spot Methods

Material Received

MCR

A. SA-21–345: Right Upper Lobe
1 block

Report electronically signed by

MCR

JESSICA PHILLIPS

Received: 23 Mar 2021 14:00

Reported: 23 Mar 2021 14:05

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292